Dyslipidemia treatment strategies in primary and secondary prevention. Dyslipemia Registry of the Spanish Arteriosclerosis Society

Introduction

Clinical studies show that patients at elevated cardiovascular risk are still far from reaching therapeutic targets, especially for LDL-C levels. It is not known whether these patients are managed differently in specialised units than in other settings.

Patients and methods

Sixty-one certified lipid units certified in the Dyslipidaemia Registry of the Spanish SVociety of Arteriosclerosis were selected for collection of the study data. We included 3958 subjects >18 years of age who met the criteria of hypercholesterolaemia (LDL cholesterol ≥160 mg/dl or non-HDL cholesterol ≥190 mg/dl) without familial hypercholesterolaemia. A total of 1665 subjects were studied with a mean follow-up of 4.2 years.

Results and conclusions

A total of 42 subjects had a cardiovascular event since they were included in the Registry, which is .6%. There were no differences in the treatment used at the start of follow-up between subjects with and without a prospective event. LDL-C improved during follow-up but 50% of the patients had not achieved the therapeutic targets at the final follow-up visit. Increased used of high- potency lipid-lowering therapy, including PCSK9 inhibitors, was observed in 16.7% of the subjects with recurrence.